http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Jinbong,Jeon, Yong-Deok,Kim, Hye-Lin,Lim, Hara,Jung, Yunu,Youn, Dong-Hyun,Jeong, Mi-Young,Kim, Hyun-Ju,Kim, Sung-Hoon,Kim, Su-Jin,Hong, Seung-Heon,Um, Jae-Young Hindawi Publishing Corporation 2013 Evidence-based Complementary and Alternative Medic Vol.2013 No.-
<P>Obesity has become a major health threat in developed countries. However, current medications for obesity are limited because of their adverse effects. Interest in natural products for the treatment of obesity is thus rapidly growing. Korean Medicine (KM) is characterized by the wide use of herbal formulas. However, the combination rule of herbal formulas in KM lacks experimental evidence. According to <I>Shennong's Classic of Materia Medica</I>, the earliest book of herbal medicine, <I>Veratrum nigrum</I> (VN) has antagonistic features against <I>Panax ginseng</I> (PG), and the PG-VN pair is strictly forbidden. In this study, we have shown the effects of PG, VN, and their combination on obesity in high-fat (HF) diet-induced obese mice and in 3T3-L1 cells. PG, VN, and PG-VN combination significantly reduced weight gain and the fat pad weight in HF diet-induced obese mice. They also significantly decreased lipid accumulation and the expressions of two major adipogenesis factors, PPAR<I><I>γ</I></I> and C/EBP<I><I>α</I></I>, in 3T3-L1 cells. In addition, the PG-VN combination had synergistic effects compared with the mixture of extracts of PG and VN on inhibition of PPAR<I><I>γ</I></I> and C/EBP<I><I>α</I></I> expressions at lower doses. These results indicate a new potential anti-obese pharmacotherapy and also provide scientific evidence supporting the usage of herbal combinations instead of mixtures in KM.</P>
( Jung Hyun Kim ),( Sun Mi Choi ),( Young Sik Park ),( Chang Hoon Lee ),( Sang Min Lee ),( Jae Joon Yim ),( Chul Gyu Yoo ),( Young Whan Kim ),( Sung Koo Han ),( Jin Woo Lee ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: The number of elderly patients admitted to the ICU is growing, along with the increasing proportion of the elderly in the general population. However, determining appropriate levels of care in these populations remains a challenge. The aim of this study to identify factors which in uence the decision whether or not to receive intensive care in elderly patients. Methods: Elderly patients over 80 year-old who were admitted to general internalmedicine wards and referred for ICU admission between January 2013 and April 2014 were retrospectively reviewed. Results: Among the 84 referred patients, 32 patients were fi nally admitted to ICU. About 64.3% of the patients were female and the mean age was 85.9 years. Baseline characteristics at the time of ICU referral were not different between the intensive care group and no intensive care group. None of the patients in both groups had advance directives before ICU referral. Factors including self-reported economic status, comorbidity of chronic lung diseases, cognition impairment, and the number of participants of DNR decision showed signifi cant difference in univariate analysis. After multivariate analysis, cognitive impairment was associated with decreased risk of ICU admission (OR 0.08; 95% CI 0.02-0.41) and increased number of family members participating in the decision making process was associated with increased risk of ICU admission (OR 3.16, 95% CI 1.03-9.66). Mean duration of hospital stay was longer in intensive care group (38.0 days) compared with no intensive care group (20.6 days) (p=0.02). However, there was no difference in hospital deaths (intensive care group86.5% vs. no intensive care group 68.8%). Conclusions: This study showed that in elders, patients with intact cognition or large number of family members participating in the decision making process, were more likely to be admitted to the ICU from general ward.
Jung Kyu Park,Chi Heum Cho,Sabarish Ramachandran,So Jin Shin,Sang Hoon Kwon,Sun Young Kwon,Soon Do Cha 대한암학회 2006 Cancer Research and Treatment Vol.38 No.2
Purpose: Sodium butyrate (NaBT) is principally a histonedeacetylase (HDAC) inhibitor, and it has the potentialto arrest HPV-positive carcinoma cells at the G1 toS phase transition of the cell cycle. The aim of study wasto determine whether phosphatidylinositol 3-kinase(PI3K) inhibition can enhance the inhibitory effect ofNaBT on a human cervical cancer cell line (HeLa).Materials and Methods: Cervical cancer cells (HeLa)were treated with NaBT alone or in combination with thePI3K inhibitors wortmannin or LY294002. Cell viabilityanalysis and FACS analysis were carried out. The expressionsof the cell cycle related proteins were evaluatedby Western-blot analysis.Results: Inhibition of PI3K enhanced NaBT-mediatedapoptosis and this decreased the HeLa cell viability.Either wortmannin or LY294002, combined with NaBT,enhanced the activation of caspase 3 and caspase 9, andthis enhanced the subsequent cleavage of poly (ADPribose)polymerase (PARP). Cervical cancer cells werearrested in the subG1 and G2/M phase, as was detectedby FACS analysis. NaBT treatment in combination withPI3K inhibitors showed the increased expression of theCDK inhibitors p21Cip1/Waf1 and p27Kip1, in a p53 dependentmanner, and also the increased dephosphorylation of Rbwhereas there was a reduction in the expression levelsof cyclin A, cyclin D1 and cyclin B1.Conclusion: The results demonstrate that inhibition ofPI3K enhances NaBT-mediated cervical cancer cell apoptosisthrough the activation of the caspase pathway.Moreover, these findings will support future investigationusing the PI3K inhibitors in combination with adjuvanttreatment for treating carcinoma of the cervix. (CancerRes Treat. 2006;38:112-117)
Sung Oh Cha,Chul Hoon Jang,Jin Oh Hong,Joon Sang Park,Jung Hyun Park 대한재활의학회 2014 Annals of Rehabilitation Medicine Vol.38 No.6
Objective We used lumbar magnetic resonance image (MRI) findings to determine possible outcome predictors of a caudal epidural steroid injection (CESI) for radicular pain caused by a herniated lumbar disc (HLD).Methods Ninety-one patients with radicular pain whose MRI indicated a HLD were enrolled between September 2010 and July 2013. The CESIs were performed using ultrasound (US). A responder was defined as having complete relief or at least a 50% reduction of pain as assessed by the visual analog scale (VAS) and functional status on the Roland Morris Disability Questionnaire (RMDQ); responder (VAS n=61, RMDQ n=51), and non-responder (VAS n=30, RMDQ n=40). MRI findings were analyzed and compared between the two groups with regard to HLD level, HLD type (protrusion or exclusion), HLD zone (central, subarticular, foraminal, and extraforaminal), HLD volume (mild, moderate, or severe), relationship between HLD and nerve root (no contact, contact, displaced, or compressed), disc height loss (none, less than half, or more than half), and disc degeneration grade (homogeneous disc structure or inhomogeneous disc structure–clear nucleus and height of intervertebral disc). Results A centrally located herniated disc was more common in the responder group than that in the non-responder group. Treatment of centrally located herniated discs showed satisfactory results. (VAS p=0.025, RMDQ p=0.040). Other factors, such as HLD level, HLD type, HLD volume, relationship to nerve root, disc height loss, and disc degeneration grade, were not critical.Conclusion The HLD zone was significant for pain reduction after CESI. A centrally located herniated disc was a predictor of a good clinical outcome.
( Sung Won Chung ),( Young Youn Cho ),( Jeong-hoon Lee ),( Young Chang ),( Joon Yeul Nam ),( Yun Bin Lee ),( Eun Ju Cho ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung-hwan Yoon ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: A number of Asian-Pacific centers perform transarterial chemoembolization (TACE) as the first treatment for advanced hepatocellular carcinoma (HCC), although sorafenib is the standard first-line treatment. In this study, we aimed to compare the overall survival (OS) according to initial treatment (TACE vs sorafenib) among patients experiencing sorafenib treatment in advanced HCC. Methods: We included 200 consecutive patients treated with sorafenib for >4 weeks with or without TACE for advanced HCC at a single tertiary hospital in Korea. The primary endpoint was OS and secondary endpoints included time to progression (TTP) and objective response rate (ORR) and disease control rate (DCR). The risk was compared between groups using a Cox proportional hazards model and inverse probability weighting (IPW) analysis. Results: Eighty-seven patients were initially treated with sorafenib (the sorafenib-first group: 54 treated with sorafenib only and 33 treated with sorafenib followed by TACE) and 113 patients were treated with TACE followed by sorafenib therapy (the TACE-first group). Twenty-eight patients (14%) were Child-Turcotte-Pugh class B and there was no significant difference in baseline characteristics between two groups except sorafenib-first group had more ascites (17.2% vs 7.1%, P=0.04) and prolonged prothrombin time (1.2±0.1 vs 1.1±0.1, P=0.02). The TACE-first group showed significantly longer OS than the sorafenib-first group (hazard ratio [HR]=0.62, 95% confidence interval [CI]=0.45-0.85, log-rank P=0.004). Median OS was 11.6 months in the TACE-first group and 6.9 months in the sorafenib-first group. The TACE-first group had significantly longer OS in multivariable analysis (adjusted HR=0.58; 95% CI=0.41-0.80, P=0.001 and IPW analysis (HR=0.63, 95% CI=0.44-0.91, P=0.01). There was no significant difference in TTP between two groups (HR=0.89, 95% CI=0.62-1.28, P=0.53). ORR was 6.9% in the sorafenib-first group and 10.6% in the TACE-first group (P=0.27 by chi-square test). DCR was 56.3% in the sorafenib-first group and 73.5% in the TACE-first group (P=0.01 by chi-square test). Conclusions: For patients with advanced HCC, second-line sorafenib treatment following TACE has significantly longer OS than first-line sorafenib treatment. An initial aggressive intrahepatic tumor control with loco-regional therapies followed by sorafenib treatment may be a potent strategy for advanced HCC.
Jung, Eun Bee,Trinh, Tuy An,Lee, Tae Kyoung,Yamabe, Noriko,Kang, Ki Sung,Song, Ji Hoon,Choi, Sungyoul,Lee, Sanghyun,Jang, Tae Su,Kim, Ki Hyun,Hwang, Gwi Seo Elsevier 2018 Journal of Ethnopharmacology Vol.213 No.-
<P><B>Abstract</B></P> <P><B>Ethnopharmacological relevance</B></P> <P> <I>Curcuma zedoaria</I> Roscoe (Zingiberaceae), also known as white turmeric or zedoaria, has been used in Ayurveda and traditional Chinese medicine to treat various cancers, and it possesses several sesquiterpenoid compounds.</P> <P><B>Objective</B></P> <P>This study aimed to evaluate the therapeutic effects of a methanolic (MeOH) extract of <I>C. zedoaria</I> rhizomes, as well as its active constituents, against gastric cancer, which is a frequently diagnosed cancer in South Korea.</P> <P><B>Materials and methods</B></P> <P>Repeated column chromatography, together with semi-preparative HPLC purification, was used to separate the bioactive constituents from the <I>C. zedoaria</I> MeOH extract. The cytotoxic effects of the <I>C. zedoaria</I> MeOH extract and its active compounds were measured in human gastric cancer AGS cells. Expression of proteins related to apoptosis was evaluated using Western blotting analysis.</P> <P><B>Results</B></P> <P>The MeOH extract of <I>C. zedoaria</I> rhizomes exerted a cytotoxic effect on AGS cells (IC<SUB>50</SUB>: 96.60 ± 4.87μg/mL). Based on the bioactivity-guided fractionation for antiproliferative activity, a chemical investigation of the MeOH extract led to the isolation of five sesquiterpenes including isoprocurcumenol (<B>1</B>), germacrone (<B>2</B>), curzerenone (<B>3</B>), curcumenol (<B>4</B>), and curcuzedoalide (<B>5</B>). Among these, curcuzedoalide demonstrated the strongest effect in suppressing gastric cancer cell proliferation in a dose-dependent manner with an IC<SUB>50</SUB> value of 125.11±2.77μM. Western blotting analysis showed that curcuzedoalide inhibited AGS human gastric cancer cell viability by activating caspase-8, caspase-9, caspase-3, and PARP, which contributed to apoptotic cell death in AGS human gastric cancer cells.</P> <P><B>Conclusion</B></P> <P>These data indicate that curcuzedoalide contributed to the cytotoxicity of <I>C. zedoaria</I> by activating the cleavage of caspases and PARP, which are representative markers for apoptosis. Therefore, curcuzedoalide is a positive candidate for the development of novel chemotherapeutics.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>